BlisselⓇ was created to release women from the symptoms of vaginal atrophy
BlisselⓇ is an ultra low dose estriol vaginal gel containing 50 micrograms per dose (1 gram) of estriol. 1,2
BlisselⓇ is indicated for treating the symptoms of vaginal atrophy due to oestrogen deficiency in postmenopausal women.1
BlisselⓇ turns back the clock on vaginal changes due to the menopause:
- Reversal of the cellular changes that lead to vaginal atrophy2:
- Significantly higher maturation value vs placebo (p0.001) after 12 weeks treatment.
- BlisselⓇ stops the pH changes that occur in vaginal atrophy2: Significantly lower pH vs placebo (p0.001) after 12 weeks treatment
Why choose a mucoadhesive gel?3
The BlisselⓇ formulation may assist the therapeutic effect whilst reducing leakage.
BlisselⓇ uses polycarbophilic components to form a mucoadhesive gel.3
This works synergistically with the estriol by providing a moisturising effect whilst increasing the retention and penetration of the hormonal component.3
Non-mucoadhesive products
Non-mucoadhesive products may have shorter vaginal contact times and produce leakage.3
Formulation
The formulation of BlisselⓇ may allow your patients to retain more of the active ingredient, whilst reducing mess and leakage.
References
- BlisselⓇ 50 micrograms/g vaginal gel. Summary of product characteristics.
- Cano A, et al. Menopause. 2012;19(10):1130-9.
- Lázaro-Carrasco de la Fuente J, et al. J Menopausal Med. 2022;28(2):60-69.
IE-CH-1362(2) DOP: October 2025
Adverse events should be reported. Reporting forms and information are available from HPRA Pharmacovigilance on the HPRA website www.hpra.ie.
Adverse events should also be reported to Consilient Health at drugsafety@consilienthealth.com or 012057766.
The information on this website is intended for Healthcare Professionals who practice in the Republic of Ireland only.